Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 VOYAGE 1 study

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Papp, Kim
Griffiths, Christopher E. M. [2 ]
Randazzo, Bruce
Wasfi, Yasmine
Shen, Yaung-Kaung
Kimball, Alexa B. [3 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England
[3] Harvard Med Sch, Dept Dermatol, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2017年 / 76卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
4768
引用
收藏
页码：AB120 / AB120
页数：1
相关论文
共 50 条
  • [1] Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
    Blauvelt, A.
    Papp, K.
    Griffiths, C. E. M.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y.
    Li, S.
    Kimball, A. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 40 - 40
  • [2] Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: Results from the phase 3 VOYAGE 2 study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [3] Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
    Gordon, K. B.
    Blauvelt, A.
    Foley, P.
    Song, M.
    Wasfi, Y.
    Randazzo, B.
    Shen, Y. K.
    You, Y.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 132 - 139
  • [4] Efficacy of switching from ustekinumab to guselkumab in patients with moderate-to-severe plaque psoriasis: Results from the NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [5] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [6] TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL
    Griffiths, C. E.
    Papp, K. A.
    Kimball, A. B.
    Randazzo, B.
    Wasfi, Y.
    Li, S.
    Shen, Y. -K.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1580 - 1581
  • [7] Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China
    Huang, He
    Liu, Hao
    Zhu, Zhengwei
    Wang, Wenjun
    Liang, Bo
    Tang, Huayang
    Yang, Sen
    Sheng, Yujun
    Sun, Liangdan
    Zhang, Xuejun
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (01) : 73 - 78
  • [8] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [9] Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : 1744 - 1749
  • [10] Efficacy responses across subgroups of patients with moderate to severe plaque psoriasis treated with Guselkumab: Results from VOYAGE 1 through 5 years
    Thaci, D.
    Foley, P.
    Puig, L.
    Merola, J. F.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. -W.
    Blauvelt, A.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 41 - 42
12345